SALT LAKE CITY and
TORONTO, Jan. 20, 2015 /PRNewswire/ --
EastGate Biotech Corp., formerly EastGate Acquisitions Corporation
(OTCBB: ETBI), an emerging pharmaceutical company exploring drug
delivery innovations for the development of novel formulations and
alternative dosage forms of existing biologically active
molecules has appointed Rose
C. Perri as President. Ms. Perri was
previously engaged in Business Development activities at EastGate
Biotech. She replaces Mirjana Hasanagic who has resigned as President
and who will now serve as the Vice President, Natural
Products. Ms. Hasanagic will remain as a
Director of EastGate's Board of Directors.
Ms. Perri brings more than 20 years of experience in
start-ups in the biotechnology and life sciences
industry. She has held managerial and
operational positions in both private and public companies that
traded on the Toronto,
Vancouver and NASDAQ
Exchanges.
"As some of our developments have matured it was time to
refine our management", says Anna
Gluskin, CEO of EastGate Biotech.
"Rose Perri not only brings a breath
of experience in the management of day-to-day operations but also
widens the company's network with the many years of building
relationships with industry partners." "We thank
Mira Hasanagic for her period as
President and look forward to working with her expertise in the
natural products field."
About EastGate Biotech Corp.
EastGate Biotech Corp. is a pharmaceutical company aimed
at utilizing drug delivery innovations for developing of improved
novel formulations and alternative dosage forms of existing
biologically active molecules. Both
pharmaceutical products and natural supplements are developed using
highly effective contemporary technologies and demonstrated
usefulness in improvement of bioavailability and biological action
of incorporated molecules. The company's product candidates
address various pharmaceutical markets, including neurological
disorders, such as epilepsy and panic attacks, infectious diseases
and diabetes. Our natural dietary supplements include
compositions for glucose regulations, urinary tract health
improvement, enhanced vitamin delivery and skin
conditions. We are working closely with clinicians and
patient advocate groups worldwide to identify existing health
issues where EastGate's approach will be most beneficial for
patient care. For more information, please visit the
company's website at
www.EastGateBiotech.com.
Cautionary statement on forward-looking
information
All statements, other than statements of historical
fact, contained or incorporated by reference in this news release
constitute "forward-looking information" or "forward-looking
statements" within the meaning of certain securities laws,
including the provisions for "safe harbour" under the United States
Private Securities Litigation Reform Act of 1995 and are based on
expectations, estimates and projections as of the date of this news
release.
The words "anticipates", "plans", "expects", "indicate",
"intend", "scheduled", "estimates", "forecasts", "focus",
"guidance", "initiative", "model", "methodology", "outlook",
"potential", "projected", "pursue", "strategy", "study", "targets",
or "believes", or variations of or similar such words and phrases
or statements that certain actions, events or results "may",
"could", "would", or "should", "might", or "way forward", "will be
taken", "will occur" or "will be achieved" and similar expressions
identify forward-looking statements. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that
are inherently subject to significant business, economic and
competitive risks, uncertainties and contingencies. The risks,
estimates, models and assumptions contained or incorporated by
reference in this release, include those identified from time to
time in the reports filed by EastGate with the SEC, which should be
considered together with any forward-looking statement.
EastGate undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Rose Perri 1-647-692-0652
Email:
information@eastgatepharmaceuticals.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/eastgate-biotech-corp-names-new-president-300022098.html
SOURCE EastGate Biotech Corp.
